13F Holdings
中文EN

NMRA Neumora Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1885522 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY19.4%
TTM EPS YoY27.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-252.7%
ROA-139.6%
ROIC (approx.)-332.4%
Asset turnover—

Leverage & solvency

Liabilities / assets80.5%
Debt / equity6.11x
Current ratio4.08x
Interest coverage-34.16x

Cash quality & payout

Operating cash flow / net income0.88x
Accruals ratio-16.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue————
R&D expense$176.06M$200.93M$142.72M$91.75M
SG&A expense$60.09M$62.54M$45.48M$31.12M
Operating income-$241.16M-$263.46M-$252.10M-$135.87M
Interest expense$2.01M$0——
Pretax income-$236.80M-$243.61M-$235.66M-$130.90M
Income tax$130,000$178,000$268,000—
Net income-$236.93M-$243.79M-$235.93M-$130.90M
EBITDA-$240.95M-$262.83M-$251.43M-$135.28M
EPS (basic)-1.45-1.53-3.63-4.81
EPS (diluted)-1.45-1.53-3.63-4.81
Weighted avg. shares (diluted)163.39M159.38M65.02M27.21M
Balance sheet
Cash & equivalents$182.53M$142.15M$374.04M$240.94M
Short-term investments—$165.43M$79.94M$130.94M
Current assets$190.54M$314.06M$478.28M$387.95M
PP&E, net$40,000$1.14M$1.79M$2.41M
Total assets$191.05M$316.97M$496.19M$426.23M
Current liabilities$32.45M$29.89M$25.11M$23.70M
Short-term debt$60.00M———
Long-term debt$54.53M$0——
Total debt$114.53M$0——
Total liabilities$87.18M$29.91M$27.12M$29.40M
Shareholders' equity$103.87M$287.06M$469.08M-$446.85M
Net debt-$68.00M-$142.15M——
Shares outstanding174.26M161.71M158.83M32.61M
Cash flow statement
Operating cash flow-$206.44M-$182.94M-$163.28M-$114.90M
Capital expenditure——$117,000$511,000
Free cash flow——-$163.40M-$115.41M
Investing cash flow$168.52M-$70.56M$64.39M-$168.01M
Financing cash flow$77.09M$21.60M$231.94M$115.74M
Depreciation & amortization$208,000$631,000$668,000$594,000
Stock-based compensation$29.88M$39.99M$17.24M$8.30M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.